Pozen Inc. v. Par Pharmaceutical, Inc.
696 F.3d 1151
Fed. Cir.2012Background
- Pozen developed sumatriptan and naproxen combination therapy for migraines and markets Treximet.
- Patents-in-suit cover methods and a multilayer tablet with sumatriptan and naproxen; Pozen listed them in the Orange Book.
- Appellants Par, Alphapharm, and DRL filed ANDAs seeking generic Treximet before patent expiry.
- District court found the patents nonobvious, valid, and infringed by the ANDA products; issued injunction.
- The case involves the '499, '458, and '183 patents and various claim constructions and doctrine-of-equivalents analyses.
- This appeal challenges validity under prior art, written description, and infringement, including the '183 patent under DOE.
Issues
| Issue | Plaintiff's Argument | Defendant's Argument | Held |
|---|---|---|---|
| Are the '499 and '458 patents invalid as obvious? | Pozen contends prior art does not teach concomitant administration. | Par/Alphapharm/DRL argue Parma, Saadah, Henry Ford records, Catarci render them obvious. | Not obvious; prior art does not teach the claimed combination with adequate motivation. |
| Is the '183 patent invalid as obvious? | Pozen argues multilayer tablet architecture supports non-obviousness. | Par asserts naproxen solubility and known multilayer solutions render it obvious. | Not obvious; claimed bilayer architecture and independent dissolution are non-obvious over the cited references. |
| Was the '499 patent properly described in written description? | The specification describes therapeutic packages and containers, satisfying written description. | Written description lacks equivalents for added terms from prosecution. | Sufficient written description; terms are adequately described in context of the disclosure. |
| Did the district court err in finding infringement of the '183 patent under the doctrine of equivalents? | Par/DRL argue 85% layer is not equivalent to 90%/95% threshold; DOE should not broaden claims. | The accused products perform substantially the same function in substantially the same way to achieve the same result. | No clear error; DOE finding affirmed that the accused products meet the 'substantially all' limitation. |
Key Cases Cited
- KSR Int'l Co. v. Teleflex Inc., 550 U.S. 398 (Supreme Court 2007) (obviousness analysis guides combining prior art to render a claim obvious)
- Graham v. John Deere Co., 383 U.S. 1 (Supreme Court 1966) (establishes framework for obviousness, including secondary considerations)
- Microsoft Corp. v. i4i Ltd. P'ship, 131 S. Ct. 2238 (Supreme Court 2011) (clear-and-convincing standard for patent validity)
- Warner-Lambert Co. v. Apotex Corp., 316 F.3d 1348 (Fed. Cir. 2003) (artificial act of infringement under 271(e)(2) and injunction framework)
- Ariad Pharm., Inc. v. Eli Lilly & Co., 598 F.3d 1336 (Fed. Cir. 2010) (written description standard for possession of invention)
- Adams Respiratory TherapeUtics, Inc. v. Perrigo Co., 616 F.3d 1283 (Fed. Cir. 2010) (doctrine of equivalents applied to ranges; all limitations rule context)
- Cohesive Techs., Inc. v. Waters Corp., 543 F.3d 1351 (Fed. Cir. 2008) (limits of doctrine of equivalents; all-limitation rule)
- Moore U.S.A., Inc. v. Standard Register Co., 229 F.3d 1091 (Fed. Cir. 2000) (range of equivalents recognition; contextual narrowness of claim terms)
- Kemin Foods, L.C. v. Pigmentos Vegetales Del Centro S.A. de C.V., 464 F.3d 1339 (Fed. Cir. 2006) (interpretation of qualitative term with specification-based guidance)